Calidi Biotherapeutics Inc.

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company focused on developing targeted genetic medicines. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic tumor sites. The platform's enveloped technology is intended to shield the virus from immune clearance, allowing it to reach tumors, induce tumor lysis, and deliver genetic medicines to metastatic locations. CLD-401, the lead candidate from the RedTail platform, is in IND-enabling studies and targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. The company is also advancing CLD-501, which utilizes a novel in situ T-cell engager approach incorporating TROP-2-targeted tumor-localized T-cell engagers alongside T-cell amplifiers for solid tumors. Updated Aug 13, 2026